Creo Medical Group PLC (LON:CREO - Get Free Report) traded down 9.5% during trading on Monday . The stock traded as low as GBX 17 ($0.22) and last traded at GBX 17.20 ($0.22). 1,215,246 shares changed hands during mid-day trading, an increase of 67% from the average session volume of 726,307 shares. The stock had previously closed at GBX 19 ($0.24).
Creo Medical Group Price Performance
The company has a 50 day moving average price of GBX 18.56 and a 200 day moving average price of GBX 21.49. The company has a market capitalization of £65.29 million, a price-to-earnings ratio of -2.56 and a beta of 0.86. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96.
Insider Activity
In related news, insider Kevin Crofton acquired 1,179,000 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average cost of GBX 17 ($0.22) per share, with a total value of £200,430 ($253,966.04). Also, insider Richard John Rees acquired 4,712 shares of the firm's stock in a transaction that occurred on Thursday, January 16th. The shares were bought at an average cost of GBX 19 ($0.24) per share, with a total value of £895.28 ($1,134.41). In the last ninety days, insiders bought 1,188,424 shares of company stock valued at $20,222,056. Company insiders own 22.43% of the company's stock.
Creo Medical Group Company Profile
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.
Further Reading
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
